ADYX - Adynxx, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
1.3000
0.0000 (0.00%)
At close: 3:47PM EDT
Stock chart is not supported by your current browser
Previous Close1.3000
Open1.2500
Bid0.0000 x 800
Ask0.0000 x 1300
Day's Range1.2500 - 1.3000
52 Week Range1.1100 - 31.4400
Volume349
Avg. Volume2,212
Market Cap7.55M
Beta (3Y Monthly)1.50
PE Ratio (TTM)N/A
EPS (TTM)-1.7520
Earnings DateAug 14, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2019-05-06
1y Target Est2.80
Trade prices are not sourced from all markets
  • GlobeNewswire

    Adynxx Reports Second Quarter 2019 Financial Results

    SAN FRANCISCO, Aug. 14, 2019 -- Adynxx, Inc. (OTCQB: ADYX), a clinical-stage biopharmaceutical company focused on the development of transcription factor decoy technology and.

  • GlobeNewswire

    Adynxx Adds Gregory J. Flesher to Board of Directors, Completes Up-listing to OTCQB Market

    Adynxx, Inc. (ADYX), a clinical-stage biopharmaceutical company focused on the development of transcription factor decoy technology and first-in-class therapeutics for the treatment of pain and inflammatory diseases, today announced that Gregory J. Flesher, Chief Executive Officer at Novus Therapeutics Inc. (NVUS), has been appointed to the Adynxx Board of Directors. In addition, Adynxx also announced today that it satisfied the requirements for listing of the Company’s shares on the OTCQB Market (OTCQB) and will begin trading on the OTCQB today.

  • GlobeNewswire

    Adynxx Stock to Move to OTC Market Following Receipt of Nasdaq Delisting Notice

    Adynxx, Inc. (ADYX), a clinical-stage biopharmaceutical company leading the development of transcription factor decoy technology and first-in-class therapeutics for the treatment of pain and inflammatory diseases, today announced that it has received written notification from The Nasdaq Stock Market affirming the delisting of the company's shares from The Nasdaq Capital Market due to noncompliance with the minimum round lot stockholders and the minimum stockholders’ equity requirement for an initial listing. The notification indicates that Nasdaq will complete the delisting process by filing a Form 25 “Notification of Delisting” with the SEC after all applicable Nasdaq review and appeal periods have lapsed. In accordance with Nasdaq’s Listing Rules, Adynxx has 15 days to decide whether to appeal the delisting determination, and the company is considering an appeal of the determination. Any such appeal would not stay the suspension of trading in the company’s common stock on Nasdaq.

  • GlobeNewswire

    Adynxx, Inc. Receives Nasdaq Notice of Delisting or Failure to Satisfy an Initial Listing Rule or Standard

    Adynxx, Inc. (Nasdaq:ADYX), a clinical-stage biopharmaceutical company leading the development of transcription factor decoy technology and first-in-class therapeutics for the treatment of pain and inflammatory diseases, today announced that it received a Staff Delisting Determination Letter from The Nasdaq Stock Market, LLC on May 6, 2019 setting forth a determination to delist Adynxx’s common stock from The Nasdaq Capital Market as a result of Adynxx’s failure to satisfy Nasdaq Listing Rule 5505(a)(3), which requires a minimum of 300 round lot holders, and Nasdaq Listing Rule 5505(b)(1)(A), which requires a minimum of $5 million in stockholders’ equity. In connection with the consummation of the merger of Adynxx with Alliqua BioMedical, Inc. and the commencement of trading of the combined organization’s common stock on The Nasdaq Capital Market, Adynxx previously announced that it expected to receive a delisting determination notifying Adynxx that Nasdaq has determined, among other things, that the combined organization does not satisfy the minimum stockholders’ equity requirement for initial listing on The Nasdaq Capital Market.